X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

CRANBURY, NJ-Kos Pharmaceuticals Inc., a specialty pharmaceutical company currently based in Miami, is headed north. The company has signed a lease for a total of 90,000 sf of headquarters and lab space at 1 Cedar Brook Dr. here.

Cushman & Wakefield’s George Keller, based in New York City, and Peter Hamburger of the firm’s East Rutherford, NJ office, represented Kos in negotiating the long-term transaction. The locally based Cedar Brook Corporate Center owns the building, which is part of a larger technology-oriented business campus. Terms of the signing were not disclosed.

The move is part of an effort by Kos to restructure its operations. The company will move its official headquarters to New Jersey, but will split its headquarters staff approximately 50-50 between here and Florida. Kos will also retain existing facilities in Weston and Hollywood, FL, as well as Raleigh, NC and Edison, NJ.

“We are making these moves for a variety of strategic business reasons,” says company president and CEO Adrian Adams. “We continue to make measured investments in all areas of our business, and in particular, research and development.

“This location is not only convenient to our Edison facility, but it is also in the epicenter of the resource-rich environment of pharmaceutical talent here,” Adams continues. He adds that the move will aid in recruiting efforts, secures space to facilitate current and future growth plans as well as provides further efficiencies along department lines.

Kos develops, makes, commercializes and markets proprietary prescription products for the treatment of chronic conditions. Its main product development strategy is to reformulate existing products with large market potential, according to Adams. The company is currently marketing Niaspan and Advicor for cholesterol disorders and Azmacort for treatment of asthma, and is developing additional products.

Kos’ new home is a freestanding, two-story building on a 7.5-acre site. The asset is built out with a pharmaceutical lab, with office and administration support space. Customization of the space is expected to be completed shortly and the company’s move-in will be phased.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 3 free articles* across the ALM subscription network every 30 days
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?

GlobeSt

Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.